SBFM SUNSHINE BIOPHARMA INC revenue, earnings and financials
For the quarter ended June 30, 2026, SUNSHINE BIOPHARMA INC reported revenue of $9.26M (down 1.6% from a year earlier), net income of −$1.56M and diluted EPS of n/a; over the last four quarters revenue was $35.3M and net income −$5.83M; for the fiscal year ended December 2025 revenue was $36.3M, up 4.1% on the year before.
SBFM annual revenue and earnings
- Fiscal year ended Dec 2025: revenue $36.3M, gross profit $12.3M, operating income −$6.23M, net income −$5.98M (margin -16.5%), EPS n/a
- Fiscal year ended Dec 2024: revenue $34.9M, gross profit $10.7M, operating income −$5.81M, net income −$5.13M (margin -14.7%), EPS −$7.32
- Fiscal year ended Dec 2023: revenue $24.1M, gross profit $8.34M, operating income −$4.79M, net income −$4.51M (margin -18.7%), EPS −$351.36
- Fiscal year ended Dec 2022: revenue $4.35M, gross profit $1.70M, operating income −$27.0M, net income −$26.7M (margin -615.4%), EPS −$1.76
- Fiscal year ended Dec 2021: revenue $228K, gross profit $111K, operating income −$2.44M, net income −$12.4M (margin -5444.4%), EPS −$4.76
SBFM quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue $9.26M (down 1.6% year over year), net income −$1.56M, EPS n/a
- Quarter ended Mar 31, 2026: revenue $8.09M (down 9.1% year over year), net income −$1.24M, EPS n/a
- Quarter ended Dec 31, 2025 (from the annual report): revenue $8.58M (down 10.6% year over year), net income −$2.14M, EPS n/a
- Quarter ended Sep 30, 2025: revenue $9.42M (up 11.6% year over year), net income −$884K, EPS n/a
- Quarter ended Jun 30, 2025: revenue $9.41M (up 1.2% year over year), net income −$1.77M, EPS −$0.82
- Quarter ended Mar 31, 2025: revenue $8.90M (up 18.0% year over year), net income −$1.18M, EPS −$0.44
- Quarter ended Dec 31, 2024 (from the annual report): revenue $9.59M (up 24.9% year over year), net income −$2.16M, EPS n/a
- Quarter ended Sep 30, 2024: revenue $8.44M (up 41.6% year over year), net income −$1.20M, EPS n/a
- Quarter ended Jun 30, 2024: revenue $9.30M (up 67.3% year over year), net income −$494K, EPS −$43.48
- Quarter ended Mar 31, 2024: revenue $7.54M (up 54.1% year over year), net income −$1.28M, EPS −$2.00
- Quarter ended Dec 31, 2023 (from the annual report): revenue $7.68M (up 94.9% year over year), net income −$1.25M, EPS n/a
- Quarter ended Sep 30, 2023: revenue $5.96M (up 4385.9% year over year), net income −$651K, EPS n/a
- Quarter ended Jun 30, 2023: revenue $5.56M (up 3599.7% year over year), net income −$902K, EPS n/a
- Quarter ended Mar 31, 2023: revenue $4.89M (up 3890.4% year over year), net income −$1.70M, EPS −$7.73
- Quarter ended Dec 31, 2022 (from the annual report): revenue $3.94M (up 4528.7% year over year), net income −$23.5M, EPS n/a
- Quarter ended Sep 30, 2022: revenue $133K (up 163.6% year over year), net income −$1.46M, EPS n/a
- Quarter ended Jun 30, 2022: revenue $150K (up 184.3% year over year), net income −$539K, EPS n/a
- Quarter ended Mar 31, 2022: revenue $123K (up 206.2% year over year), net income −$1.24M, EPS −$0.23
- Quarter ended Dec 31, 2021 (from the annual report): revenue $85.1K, net income $667K, EPS n/a
- Quarter ended Sep 30, 2021: revenue $50.4K, net income −$4.04M, EPS n/a
SBFM cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$5.33M, share buybacks $0
- Fiscal year ended Dec 2024: operating cash flow −$12.5M, share buybacks $3.14M
- Fiscal year ended Dec 2023: operating cash flow −$8.78M, share buybacks $541K
- Fiscal year ended Dec 2022: operating cash flow −$5.25M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$1.83M, share buybacks n/a
SBFM balance sheet
- Jun 30, 2026: cash n/a, total assets $33.6M, total liabilities $6.09M, shareholders' equity $27.5M
- Mar 31, 2026: cash n/a, total assets $27.9M, total liabilities $6.41M, shareholders' equity $21.5M
- Dec 31, 2025: cash n/a, total assets $30.1M, total liabilities $7.04M, shareholders' equity $23.0M
- Sep 30, 2025: cash n/a, total assets $31.5M, total liabilities $7.29M, shareholders' equity $24.2M
- Jun 30, 2025: cash n/a, total assets $32.0M, total liabilities $6.28M, shareholders' equity $25.7M
- Mar 31, 2025: cash n/a, total assets $29.2M, total liabilities $6.48M, shareholders' equity $22.7M
- Dec 31, 2024: cash n/a, total assets $30.6M, total liabilities $7.06M, shareholders' equity $23.5M
- Sep 30, 2024: cash n/a, total assets $30.1M, total liabilities $5.02M, shareholders' equity $25.0M
What is SBFM's revenue?
SUNSHINE BIOPHARMA INC reported $35.3M of revenue over its last four quarters, through June 30, 2026.
Is SBFM profitable?
No. SUNSHINE BIOPHARMA INC lost $5.83M over the last four quarters.